L2L Microarray Analysis Tool
Results for P01AX.profile.d50
| Results summary | View all lists in L2L MDB | View all genes in P01AX.profile.d50 |
| List Name | Description | Total probes |
Expected matches |
Actual matches |
Fold Enrichment |
Binomial p-value |
|---|---|---|---|---|---|---|
| tgfb_hmvec_2hr_up | Up-regulated 2 hr following treatment of human microvessel endothelial cells (HMVEC) with TGFbeta. | 1997 | 4.94 | 17 | 3.44 | 1.64e-05 |
| tgfb_hmvec_4hr_up | Up-regulated 4 hr following treatment of human microvessel endothelial cells (HMVEC) with TGFbeta. | 1997 | 4.94 | 17 | 3.44 | 1.64e-05 |
| alk1_hmvec_2hr_up | Up-regulated 2 hr following constitutive activation of TGFbeta receptor ALK1, which activates the Smad1/5 pathway, in human microvessel endothelial cells (HMVEC). | 593 | 1.47 | 8 | 5.46 | 1.41e-04 |
| alk1_hmvec_4hr_up | Up-regulated 4 hr following constitutive activation of TGFbeta receptor ALK1, which activates the Smad1/5 pathway, in human microvessel endothelial cells (HMVEC). | 593 | 1.47 | 8 | 5.46 | 1.41e-04 |
| bay_pbmc_4hr_up | Up-regulated at 4 hr following treatment of peripheral blood mononuclear cells (PBMC) with BAY 50-4798, an IL-2 receptor agonist. | 544 | 1.34 | 7 | 5.21 | 4.80e-04 |
| et743_sarcoma_24hrs_dn | Down-regulated at 24 hours following treatment with Et-743 in at least 8 of 11 sarcoma cell lines | 163 | 0.40 | 4 | 9.93 | 7.74e-04 |
| brca_prognosis_neg | Genes whose expression is consistently negatively correlated with breast cancer outcomes - higher expression is associated with metastasis and poor prognosis | 166 | 0.41 | 4 | 9.75 | 8.28e-04 |
| il2_pbmc_24hr_dn | Down-regulated at 24 hr following treatment of peripheral blood mononuclear cells (PBMC) with recombinant IL-2. | 646 | 1.60 | 7 | 4.38 | 1.30e-03 |
| bay_pbmc_48hr_up | Up-regulated at 48 hr following treatment of peripheral blood mononuclear cells (PBMC) with BAY 50-4798, an IL-2 receptor agonist. | 475 | 1.17 | 6 | 5.11 | 1.32e-03 |
| uvb_nhek3_c7 | Regulated by UV-B light in normal human epidermal keratinocytes, cluster 7 | 86 | 0.21 | 3 | 14.11 | 1.33e-03 |
| reovirus_hek293_dn | Down-regulated at any timepoint up to 24 hours following infection of HEK293 cells with reovirus strain T3Abney | 488 | 1.21 | 6 | 4.97 | 1.51e-03 |
| alk5_hmvec_2hr_up | Up-regulated 2 hr following constitutive activation of TGFbeta receptor ALK5,, which activates the Smad2/3 pathway, in human microvessel endothelial cells (HMVEC). | 347 | 0.86 | 5 | 5.83 | 1.87e-03 |
| alk5_hmvec_4hr_up | Up-regulated 4 hr following constitutive activation of TGFbeta receptor ALK5,, which activates the Smad2/3 pathway, in human microvessel endothelial cells (HMVEC). | 347 | 0.86 | 5 | 5.83 | 1.87e-03 |
| il2_pbmc_4hr_up | Up-regulated at 4 hr following treatment of peripheral blood mononuclear cells (PBMC) with recombinant IL-2. | 510 | 1.26 | 6 | 4.76 | 1.88e-03 |
| il2_pbmc_48hr_up | Up-regulated at 48 hr following treatment of peripheral blood mononuclear cells (PBMC) with recombinant IL-2. | 511 | 1.26 | 6 | 4.75 | 1.90e-03 |
| p21_middle_dn | Down-regulated at intermediate timepoints (12-16 hrs) follwing ectopic expression of p21 (CDKN1A) in OvCa cells | 26 | 0.06 | 2 | 31.12 | 1.91e-03 |
| tgfb_hmvec_4hr_dn | Down-regulated 4 hr following treatment of human microvessel endothelial cells (HMVEC) with TGFbeta. | 1321 | 3.27 | 10 | 3.06 | 2.00e-03 |
| stemcell_neural_up | Enriched in mouse neural stem cells, compared to differentiated brain and bone marrow cells | 2805 | 6.93 | 16 | 2.31 | 2.17e-03 |
| et743_sarcoma_72hrs_dn | Down-regulated at48 hours following treatment with Et-743 in at least 6 of 8 sarcoma cell lines | 376 | 0.93 | 5 | 5.38 | 2.64e-03 |
| tpa_skin_up | Upregulated in murine dorsal skin cells 6 hours after treatment with the phorbol ester carcinogen TPA | 31 | 0.08 | 2 | 26.10 | 2.71e-03 |
| csb_robust_up | Up-regulated robustly by stable expression of wt CSB in hTERT-immortalized CS1AN CSB-null fibroblasts vs. eGFP-expressing controls (9 of 9 pairwise comparisons). | 140 | 0.35 | 3 | 8.67 | 5.25e-03 |
| uvc_high_all_dn | Down-regulated at any timepoint following treatment of WS1 human skin fibroblasts with UVC at a high dose (50 J/m^2) (clusters d1-d9) | 634 | 1.57 | 6 | 3.83 | 5.41e-03 |
| 5azac-tsa_hepg2_dn | Down-regulated in human hepatoma cells (HepG2) following 24 hrs treatment with 2.5 microM 5-aza-2-deoxycytidine (5azaC) and 24 hrs treatment with both 5azaC and 500 nM trichostatin A (TSA). | 2343 | 5.79 | 13 | 2.24 | 6.65e-03 |
| 5azac_hepg2_dn | Down-regulated in human hepatoma cells (HepG2) following 48 hrs treatment with 2.5 microM 5-aza-2-deoxycytidine (5azaC). | 1830 | 4.52 | 11 | 2.43 | 6.85e-03 |
| p21_any_dn | Down-regulated at any timepoint (4-24 hrs) follwing ectopic expression of p21 (CDKN1A) in OvCa cells | 50 | 0.12 | 2 | 16.18 | 6.92e-03 |
| et743_sarcoma_48hrs_dn | Down-regulated at48 hours following treatment with Et-743 in at least 8 of 11 sarcoma cell lines | 304 | 0.75 | 4 | 5.32 | 7.25e-03 |
| alzheimers_incipient_dn | Downregulated in correlation with incipient Alzheimer's Disease, in the CA1 region of the hippocampus | 312 | 0.77 | 4 | 5.19 | 7.92e-03 |
| cox1_ko_cortex_dn | Down-regulated in the cerebral cortex of COX1-/- mice compared to wild-type controls. | 57 | 0.14 | 2 | 14.19 | 8.91e-03 |